Loading...

HROW HARROW INC Company Mergers 8-K Filing

HRRW

HRW

HARROW INC

(HROW)

2025 8-K

New Senior Notes Issued

Debt Offering Announced

Note Offering Launch

Investor Conference Disclosure

Financial Results Update

Management Change

Harrow Acquisition

Financial Update

Leadership Change

Merger Agreement Filed

Credit Agreement Secured

Investor Day Announcement

Merger Announcement

Accounting Firm Changes

Debt Offering Announcement

New Credit Facility

Management Changes

Financial Statements

Financial Results

Earnings Announcement

Board Resignation

Financial Results

Credit Agreement Amendment

Investor Presentation

Earnings Reports

Accounting Firm Change

Annual Meeting of Stockholders

Financial Results Announcement

CMS Approval for MUE Increase

Confirmation of IHEEZO's se...

Earnings Reports

Licensing Agreement with Ap...

Board Expansion and New Dir...

Termination of Loan Agreement

Financial Results Announcement

Resignation of Director

Financial Results Announcement

Equity Offerings

Asset Acquisitions, Debt Re...

Annual Meeting of Stockholders

Financial Results Announcement

Loan Agreement with Oaktree...

Financial Results Announcement

Acquisition of Ophthalmic P...

Issuance of Senior Notes

External Links:

On June 9, 2025, Harrow, Inc. entered into a license and supply agreement with Formosa Pharmaceuticals to market BYQLOVI, committing to a $500,000 payment upon first sale and potential future payments based on sales performance.

AI Assistant

HARROW INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.